Brussels, 13/02/2015 (Agence Europe) - ANSM, the French medicines agency, announced on 11 February that it had asked the European Commission's Standing Committee on Medicinal Products for Human Use to re-examine the marketing of the anti-obesity medicine Mysimba.
The European Medicines Agency (EMA) delivered a favourable opinion on authorising the marketing of this appetite suppressant on 19 December 2014 but France and Ireland voted against this opinion, believing that the medicine's...